FIELD: chemistry.
SUBSTANCE: isolated peptide having cytotoxic T lymphocyte (CTL) inducing capacity in the presence of an antigen-presenting cell bearing HLA-A*2402, is used to obtain antigen-presenting cells and therefore CTL. The obtained CTL are used for targeted action against CDCA1-expressing cancer cells.
EFFECT: invention provides an effective vaccine for inducing anti-tumour immunity in a subject.
16 cl, 4 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2699543C2 |
| MODIFIED MELK PEPTIDES AND VACCINES CONTAINING LATTER | 2011 |
|
RU2580035C2 |
| FOXM1 PEPTIDES AND VACCINES CONTAINING THEM | 2010 |
|
RU2560431C2 |
| URLC10-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2700881C2 |
| KOC1-DERVIED PEPTIDE AND VACCINE INCLUDING SAME | 2015 |
|
RU2699542C2 |
| TEM8 PEPTIDES AND VACCINES CONTAINING THEM | 2008 |
|
RU2498993C2 |
| PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
| HJURP PEPTIDES AND VACCINES CONTAINING THEM | 2011 |
|
RU2570560C2 |
| UBE2T PEPTIDE AND VACCINES CONTAINING THE SAME | 2013 |
|
RU2663350C2 |
| TOPK PEPTIDES AND THEIR VACCINES | 2012 |
|
RU2633503C2 |
